

# Iron(0)-Catalyzed Transfer Hydrogenative Condensation of Nitroarenes with Alcohols: A Straightforward Approach to Benzoxazoles, Benzothiazoles, and Benzimidazoles

Ramachandra Reddy Putta, Simin Chun, Seung Hyun Choi, Seok Beom Lee, Dong-Chan Oh, and Suckchang Hong\*



Cite This: <https://dx.doi.org/10.1021/acs.joc.0c02191>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

**ABSTRACT:** The iron-catalyzed hydrogen transfer strategy has been applied to the redox condensation of *o*-hydroxynitrobenzene with alcohol, leading to the formation of benzoxazole derivatives. A wide range of 2-substituted benzoxazoles were synthesized in good to excellent yields without the addition of an external redox agent. A series of control experiments provided a plausible mechanism. Furthermore, the reaction system was successfully extended to the synthesis of benzothiazoles and benzimidazoles.



## INTRODUCTION

Benzazoles (benzoxazoles, benzothiazoles, and benzimidazoles) are common structures in many natural products and synthetic drugs. In particular, 2-substituted benzazoles are considered a core moiety in drug discovery because of their wide range of biological activities.<sup>1</sup> In addition to biological applications, these compounds have been applied in fluorescent chemosensors<sup>2</sup> and other functional materials.<sup>3</sup> Because of the important pharmaceutical and industrial applications, many synthetic protocols for benzazole derivatives have been developed. The most straightforward approach involves condensation of *o*-hydroxy/mercapto/amino anilines with carbonyl compounds, in particular, an aldehyde.<sup>4</sup> Compared with labile aldehydes, low-oxidation-level substrates, such as alcohol and amine, are readily available and usually supplied as feedstock. Based on these advantages, low-oxidation-level substrates have been employed in the synthesis of benzazoles via oxidative annulation, which is initiated by in situ formation of aldehyde or imine intermediate.<sup>5</sup> Moreover, metal-catalyzed cyclization of *o*-haloanilides was also reported for the synthesis of benzazoles.<sup>6</sup>


In recent years, redox condensation of nitroarenes with low-oxidation-level substrates has attracted much attention of organic chemists. Nitroarenes are usually considered a precursor of aniline, and they can be reduced to aniline by a redox process with a low-oxidation-level partner. Redox condensation provides an efficient synthetic approach to benzazole motifs from readily available starting materials through a one-pot reaction. Nguyen et al. developed a Fe/S-

catalyzed cyclization of *o*-substituted nitrobenzenes with 4-picoline, alkyl amines, and aryl acetic acids to form 2-aryl benzazoles.<sup>7</sup> Inspired by that report, Gan et al. extended similar Fe/S redox systems to benzyl chlorides and disulfides.<sup>8</sup> Pd-catalyzed carbonylative coupling of *o*-substituted nitrobenzenes with aryl halides has also been reported; however, stoichiometric Fe(CO)<sub>5</sub> was used as a carbonyl source and reducing reagent.<sup>9</sup> Alcohols have received more attention as reducing partners because of their availability in a wide range of structures. Indeed, alcohols have been widely applied in redox condensations with *o*-nitrophenols and *o*-nitroaniline, leading to the corresponding benzazoles.<sup>10</sup> These reactions usually proceed using a specific metal catalyst or heterogeneous catalyst. However, the formation of organic waste and the use of excess alcohols are often major concerns. Therefore, an efficient synthetic method for these benzazoles from simple and readily available starting materials is still desirable.

Tricarbonyl ( $\eta^4$ -cyclopentadienone) iron(0) complexes have been extensively applied to construct C–N, C–C, and C–O bonds through a hydrogen-borrowing strategy.<sup>11</sup> In this strategy, alcohol can be applied as both a coupling partner and a reductant. Using this iron complex, we recently reported

Received: September 10, 2020

## Scheme 1. Synthesis of Benzazoles from Nitroarene through a Redox Strategy



the synthesis of benzimidazoles via acceptorless dehydrogenative coupling of alcohols with 1,2-diaminobenzene.<sup>12</sup> Based on our previous work, we envisioned that nitroarenes could be applied as a hydrogen acceptor to balance the transfer of hydrogen. Even if the hydrogenation of C=O, C=N, and C=C bonds has been reported using this iron complex, a reduction of nitro group via hydrogen transfer has rarely been investigated to date. Herein, we report a facile synthesis of 2-substituted benzazoles by iron-catalyzed transfer hydrogenative annulation of *o*-nitrophenol/thiophenol/aniline with alcohols (Scheme 1). No additional redox reagents were needed, and only water was generated as a byproduct in this transformation.

## RESULTS AND DISCUSSION

We began the optimization study for the transfer hydrogenative condensation of *o*-nitrophenol **1a** using benzyl alcohol **2a** as a reducing partner (Table 1). The preliminary reaction was

**Table 1. Optimization of the synthesis of 2-phenylbenzoxazole<sup>a</sup>**

entry	2a (equiv)	solvent	yield (%) <sup>b</sup>	
			3aa	3aa'
1 <sup>c</sup>	2.0	toluene	51	48
2	2.0	toluene	58	25
3	2.0	<i>o</i> -xylene	77	11
4	2.0	CPME	74	10
5	1.5	CPME	87	
6	1.5	<i>o</i> -xylene	89	
7 <sup>d</sup>	1.5	<i>o</i> -xylene	67	
8	1.0	<i>o</i> -xylene	51	


<sup>a</sup>Reaction conditions: **1a** (0.4 mmol), **2a** (0.4–0.8 mmol), **Fe 1** (2 mol %),  $\text{Me}_3\text{NO}$  (4 mol %), and solvent (1 mL) in a sealed tube at 150 °C for 24 h. <sup>b</sup>Isolated yield. <sup>c</sup>**Fe 1** (3 mol %),  $\text{Me}_3\text{NO}$  (6 mol %). <sup>d</sup>**Fe 1** (1.5 mol %),  $\text{Me}_3\text{NO}$  (3 mol %).

carried out using **Fe 1** as a catalyst (3 mol %), and the expected 2-phenylbenzoxazole **3aa** was isolated in 51% yield along with 2-(benzylamino) phenol **3aa'** (entry 1). We supposed that the catalyst could mediate imine reduction competitively with the annulation process. To suppress the formation of **3aa'**, catalyst loading was reduced to 2 mol % and the formation of **3aa'** was significantly decreased (entry 2). Moreover, *o*-xylene and cyclopentyl methyl ether (CPME) afford benzoxazole **3aa** more selectively than toluene (entries 3 and 4). When alcohol **2a** was decreased from 2.0 to 1.5 equiv, an excellent yield of **3aa** was achieved without side product **3aa'** (entries 5 and 6). Further decreasing the quantities of catalyst or alcohol gave a negative result on the reaction (entries 7 and 8). In addition, various iron complexes, including commercially available  $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$  and  $\text{Fe}_2(\text{CO})_9$ , were screened to determine the best catalyst in the reaction condition. Among these complexes, **Fe 1** showed the highest activity in transfer hydrogenative condensation (see details in the Supporting Information). All reactions were carried out under pressure in a sealed tube to enhance the efficiency of hydrogen transfer, especially for the reduction of nitro group.

With the optimized conditions, we investigated the substrate scope for transfer hydrogenative condensation between *o*-nitrophenol **1** and alcohol **2** (Table 2). Various benzyl alcohols afforded the desired benzoxazole products **3ab–al** in high yields (70–97%). In the case of alcohols with strong electron-withdrawing groups such as  $\text{CO}_2\text{Me}$  and CN, benzoxazole products were obtained in lower yields (**3al–an**). Generally, an alcohol with a *para*-substituent provided the desired products in a slightly higher yield than that of an alcohol with *meta*- and *ortho*-substituents (**3ab–ag**). A series of alcohols containing heterocycles (furan, thiophene, and pyridine) also gave the corresponding products (**3aq–as**). In addition to benzylic alcohols, allyl and alkyl alcohols were explored. Although the yields were lower than those achieved by benzylic alcohols, the allyl and alkyl alcohols could afford the desired products (**3at**, **3au**). It is important to note that a small amount of *o*-aminophenol, which might be generated in situ by hydrogenation of **1a**, was observed in some cases.

Next, variously substituted *o*-nitrophenols **1** were used for transfer hydrogenative condensation with benzyl alcohol **2a**. Electron-rich nitrophenols tend to afford products in higher yields than electron-deficient nitrophenols (**3ba–ea**). In

Table 2. Reaction Scope for Benzoxazoles




particular, CN- and COCH<sub>3</sub>-substituted **1** gave the desired products in low yields (**3ja**, **3ka**). Although we could not observe any reduced products, a trace amount of aldol condensation product was observed in the reaction for **3ka**. These results indicate that the nitrophenol **1** bearing electron-rich substituents facilitate the transfer hydrogenative annulation higher than those of electron-withdrawing substituents. If there was a substituent at the *ortho*-position to the OH group in nitrophenol, benzoxazole products were obtained in lower yields (**3ga–ia**). No hydrogenated or reduced products were observed in the reaction containing substituents that could be affected by hydrogenation, such as halogen, ester, and nitrile. The tolerance of various functional groups opens the pathway for further modifications of the benzoxazole products. Furthermore, the practical utility of the developed method was demonstrated by the gram-scale reaction of **3ah** (73%).

After the successful synthesis of benzoxazoles from *o*-nitrophenol, we envisioned that benzothiazole and benzimidazoles could also be synthesized by replacing *o*-nitrophenol with *o*-nitrothiophenol/aniline. First, we explored the feasibility of benzothiazole formation between *o*-nitrothiophenol **4a** and benzyl alcohol **2a** using the above reaction conditions. Freshly prepared *o*-nitrothiophenol **4a** was used in the reaction since **4a** is unstable and easily undergoes dimerization to 2,2'-dinitrodiphenyl disulfide itself. However, a low yield of the desired benzothiazole **5aa** was obtained (30%) along with the

dimerized disulfide product. When we added 1 equiv of <sup>t</sup>BuONa to suppress the dimerization of **4a**, the yield of **5aa** was significantly increased to 71% (Scheme 2). 3-Pyridine and 1-naphthalene were also successfully substituted on the 2-position of benzothiazole with good yields (**5as**, **5av**).

Scheme 2. Synthesis of Benzothiazoles



To further extend the reaction system, we employed *o*-nitroaniline **6a** as a substrate to explore the possibility of benzimidazole formation (Table 3). While no annulated

Table 3. Optimization Studies for the Synthesis of 2-Phenylbenzimidazole<sup>a</sup>

Reaction scheme for the synthesis of 2-phenylbenzimidazole **7aa** from *o*-nitroaniline **6a** and benzyl alcohol **2a**. Conditions: Fe **1**, Me<sub>3</sub>NO, <sup>t</sup>BuONa, solvent, 150 °C.


entry	<sup>t</sup> BuONa (equiv)	solvent	time (h)	yield (%) <sup>b</sup>
1		<i>o</i> -xylene	24	
2	1.0	<i>o</i> -xylene	24	19
3	1.0	toluene	24	15
4	1.0	CPME	24	45
5	1.0	1,4-dioxane	24	18
6	1.0	chlorobenzene	24	62
7	1.0	chlorobenzene	42	75
8 <sup>c</sup>	1.0	chlorobenzene	42	70
9	1.5	chlorobenzene	42	80

<sup>a</sup>Reaction conditions: **6a** (0.4 mmol), **2a** (0.6 mmol), Fe **1** (2 mol %), Me<sub>3</sub>NO (4 mol %), <sup>t</sup>BuONa (0.4–0.8 mmol), and solvent (1 mL) in a sealed tube at 150 °C. <sup>b</sup>Isolated yield. <sup>c</sup>160 °C.

products could be detected under the standard conditions, significant amounts of 1,2-diaminobenzene and benzaldehyde, which can be generated through hydrogen transfer, were observed (entry 1). Based on our experience and previous reports,<sup>10d,g,12</sup> we expected that a stoichiometric base is required for the formation of benzimidazole. The screening of bases was followed, and <sup>t</sup>BuONa was found to be the most appropriate one (entry 2), whereas other bases (<sup>t</sup>BuOK, KOH, and K<sub>2</sub>CO<sub>3</sub>) gave only trace amounts of benzimidazole **7aa** (results are not shown). Considering the more polar character of benzimidazole than benzoxazoles and benzothiazoles, we assumed that solvent may be a crucial factor in the benzimidazole synthesis. Thus, we examined the solvent effect and revealed that chlorobenzene is the best solvent (entries 2–6). A longer reaction time afforded **7aa** in higher yield (entry 7), and a slightly diminished yield was observed at a higher temperature (entry 8). The highest yield of **7aa** was obtained by increasing the quantity of base to 1.5 equiv (entry 9, 80%).

With the optimal conditions in hand, the scope of alcohol substrates was investigated for the synthesis of benzimidazole (Table 4). Similar to benzoxazole, benzyl alcohols with


**Table 4. Scope of Alcohols for the Synthesis of Benzimidazoles**



electron-donating groups (7af, 7ah) are more favorable than those having electron-withdrawing groups (7ag, 7aj). Heteroaryl-substituted alcohols also afforded the desired products 7ar and 7as in satisfactory yields. Notably, any 1,2-disubstituted benzimidazole products were not observed in the reaction, which is often problematic in the selective synthesis of benzimidazole.

Several control experiments were performed to investigate the reaction mechanism (Scheme 3). When the reaction was

**Scheme 3. Mechanism Studies**




carried out in the absence of a catalyst, any products were not observed (Scheme 3a). This result indicates the vital role of iron catalyst in the hydrogen transfer. As shown in Scheme 3b, benzaldehyde 2a' was applied directly in the reaction instead of 2a. However, nitro reduction of 1a did not occur and no products were observed. If *o*-aminophenol 1a' was treated with 2a, no desired product was detected, and a small amount of 3aa' was observed (Scheme 3c). *N*-Benzyl product 3aa' could

be formed via the C–N bond formation by transfer hydrogenation between amine 1a' and alcohol 2a. These experiments revealed that both hydrogen acceptors and hydrogen donors are required for iron-catalyzed hydrogen transfer. Furthermore, the reaction of pre-reduced 1a' with pre-oxidized 2a' could not produce the desired product 3aa, and most of starting materials remained (Scheme 3d). We speculated that imine formation and cyclization between 1a' and 2a' are reversible until the final oxidative aromatization. Therefore, the iron complex was determined not only to serve as a hydrogen mediator between the nitro and alcohol groups but also to be involved in the final oxidative aromatization to form the desired product 3aa. To determine the key redox intermediates, secondary alcohol 2w was applied in the reaction as a reducing partner (Scheme 3e). Although annulation did not occur, both *o*-aminophenol 1a' and ketone 2w were directly obtained. This result confirmed that the alcohol is oxidized into the corresponding carbonyl intermediate and that the nitro group is reduced to an amino group in situ by iron-catalyzed hydrogen transfer process.

Based on the above-described experiments, a plausible mechanism of the transfer hydrogenative condensation for benzoxazole was proposed, as depicted in Scheme 4. First, the

**Scheme 4. Proposed Mechanism for the Synthesis of Benzoxazole**



iron catalyst Fe 1 is activated by Me<sub>3</sub>NO to form 16-electron iron species [Fe]. [Fe] mediates the oxidation of alcohol 2a and generates [Fe]-H<sub>2</sub>, which reduces nitrophenol 1a to amino-phenol 1a'. Condensation of the oxidized aldehyde 2a' with 1a' produces imine intermediate I, followed by cyclization to form intermediate II. All steps from 1a' and 2a' to intermediate II are reversible; thus, [Fe]-mediated oxidative aromatization of II leads to completion of benzoxazole 3aa. In the case of benzimidazole synthesis, the oxidative aromatization did not occur with [Fe] alone, and the base helps to complete the benzimidazole synthesis at this step. As mentioned above, we

also identified **3aa'** as a side product, which might be generated from imine **1** by [Fe]-H<sub>2</sub> mediated hydrogenation.

## CONCLUSIONS

In conclusion, we have described the iron-catalyzed transfer hydrogenative condensation of nitroarenes with alcohol for the synthesis of benzoxazoles. Tricarbonyl ( $\eta^4$ -cyclopentadienone) iron(0) complexes have been applied in a hydrogen transfer strategy between nitro and alcohol functionalities. This is a pioneering work on the reduction of nitro group via hydrogen transfer using this type of iron complex. A wide range of benzoxazole derivatives were synthesized in good to excellent yields. A plausible mechanism for benzoxazole formation was presented based on the control experiments. The main advantages of the developed method are that no additional oxidants or reductants were required, and only water was generated as a stoichiometric byproduct. Moreover, the reaction system was successfully extended to the synthesis of benzothiazoles and benzimidazoles. Therefore, this methodology provides an efficient alternative for the synthesis of benzoxazole derivatives. Further extension to access other types of *N*-heterocycles using an iron-catalyzed hydrogen transfer strategy is under investigation in our research group.

## EXPERIMENTAL SECTION

**General Information.** All catalytic reactions were carried out under an argon atmosphere using a sealed tube. Iron complexes **Fe 1–5** and **Fe 6** were prepared according to the literature.<sup>13,14</sup> All commercially available reagents and solvents (purchased from Sigma-Aldrich, TCI, Alfa Aesar, and Acros Organics) were used without further purification unless otherwise noted. Reactions were monitored by thin-layer chromatography on a silica gel 60 F254 plate using UV illumination at 254 nm. Column chromatography was performed on silica gel (230–400 mesh) using a mixture of *n*-hexane/ethyl acetate or dichloromethane (DCM)/methanol as eluents. Nuclear magnetic resonance (<sup>1</sup>H NMR, <sup>13</sup>C NMR, <sup>19</sup>F NMR) spectra were measured on JEOL JNM-ECZ400s [400 MHz (<sup>1</sup>H), 100 MHz (<sup>13</sup>C), 376 MHz (<sup>19</sup>F)] using CDCl<sub>3</sub> or DMSO-*d*<sub>6</sub> as solvent. The chemical shifts are given in parts per million (ppm) on the delta ( $\delta$ ) scale. The solvent peak was used as a reference value, for <sup>1</sup>H NMR: CDCl<sub>3</sub> = 7.26 ppm, DMSO-*d*<sub>6</sub> = 2.50 ppm; for <sup>13</sup>C{<sup>1</sup>H} NMR: CDCl<sub>3</sub> = 77.16 ppm, DMSO-*d*<sub>6</sub> = 39.52 ppm. Coupling constants (*J*) are expressed in hertz (Hz). IR spectra were recorded on a JASCO, FT/IR-4200 infrared spectrophotometer and are reported in cm<sup>-1</sup>. All high-resolution mass spectra (HRMS) were acquired under fast atom bombardment (FAB) mode on a JMS-700 MStation mass spectrometer using a double-focusing magnetic sector. Melting points were measured on a Büchi B-540 melting point apparatus and were not corrected.

**Synthesis of Benzoxazoles. General Procedure A.** A mixture of *o*-nitrophenol (0.4 mmol, 1.0 equiv), alcohol (0.6 mmol, 1.5 equiv), **Fe 1** (3.35 mg, 0.008 mmol), and Me<sub>3</sub>NO (1.2 mg, 0.016 mmol) was placed in a dried 10 mL sealed tube. The tube was degassed and backfilled with argon three times; then, *o*-xylene (1 mL) was added using a syringe under argon flow. The reaction tube was capped, and then the mixture was stirred and heated at 150 °C in an oil bath for 24 h. After completion, the reaction mixture was cooled to room temperature and volatiles were removed under reduced pressure. The residue was purified by silica gel column chromatography using *n*-hexane/ethyl acetate as an eluent to afford the desired benzoxazole derivatives **3**.

**2-Phenylbenzo[d]oxazole (3aa).** Following the general procedure A with **1a** (55.6 mg) and **2a** (62  $\mu$ L), **3aa** was obtained as a white solid (69.5 mg, 89% yield). Mp 103–105 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.26–8.28 (m, 2H), 7.79 (q, *J* = 3.0 Hz, 1H), 7.60 (q, *J* = 3.0 Hz, 1H), 7.52–7.55 (m, 3H), 7.35–7.38 (m, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  163.2, 150.9, 142.2, 131.7, 129.0, 127.8, 127.3, 125.2, 124.7, 120.1, 110.7. HRMS

(FAB<sup>+</sup>) *m/z* calcd for C<sub>13</sub>H<sub>10</sub>NO [M + H]<sup>+</sup>: 196.0762, found: 196.0759.

**2-(Benzylamino)phenol (3aa').** Following the general procedure A with **1a** (55.6 mg) and **2a** (0.8 mmol, 83  $\mu$ L), **3aa'** was obtained as colorless oil (8.8 mg, 11% yield). Eluent: *n*-hexane/ethyl acetate (90/10). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.34–7.41 (m, 4H), 7.26–7.30 (m, 1H), 6.84 (t, *J* = 7.4 Hz, 1H), 6.62–6.73 (m, 3H), 4.63 (s, 1H), 4.36 (s, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  143.5, 139.5, 137.1, 128.713, 127.7, 127.3, 121.9, 117.9, 114.4, 112.6, 48.7. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>13</sub>H<sub>13</sub>NO [M + H]<sup>+</sup>: 199.0997, found: 199.0993.

**2-(*o*-Tolyl)benzo[d]oxazole (3ab).** Following the general procedure A with **1a** (55.6 mg) and **2b** (73.3 mg), **3ab** was obtained as a white solid (70 mg, 84% yield). Mp 69–71 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.17–8.19 (m, 1H), 7.81 (dd, *J* = 5.7, 3.4 Hz, 1H), 7.60 (q, *J* = 3.1 Hz, 1H), 7.35–7.42 (m, 5H), 2.82 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  163.5, 150.4, 142.2, 139.0, 131.9, 131.0, 130.1, 126.3, 126.2, 125.1, 124.5, 120.2, 110.6, 22.4. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>14</sub>H<sub>12</sub>NO [M + H]<sup>+</sup>: 210.0919, found: 210.0912.

**2-(2-Fluorophenyl)benzo[d]oxazole (3ac).** Following the general procedure A with **1a** (55.6 mg) and **2c** (65  $\mu$ L), **3ac** was obtained as a white solid (59.9 mg, 70% yield). Mp 97–99 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.25 (td, *J* = 7.5, 1.7 Hz, 1H), 7.83–7.85 (m, 1H), 7.61–7.64 (m, 1H), 7.51–7.54 (m, 1H), 7.38–7.41 (m, 2H), 7.30–7.34 (m, 1H), 7.26–7.28 (m, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.9 (d, *J* = 256.8 Hz), 159.5 (d, *J* = 4.8 Hz), 150.6, 141.9, 133.2 (d, *J* = 8.7 Hz), 130.6, 125.6, 124.6 (d, *J* = 2.9 Hz), 124.6, 120.5, 117.2 (d, *J* = 21.1 Hz), 115.6 (d, *J* = 10.5 Hz), 110.81. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -110.0. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>13</sub>H<sub>9</sub>FNO [M + H]<sup>+</sup>: 214.0668, found: 214.0664.

**2-(*m*-Tolyl)benzo[d]oxazole (3ad).** Following the general procedure A with **1a** (55.6 mg) and **2d** (73.3 mg), **3ad** was obtained as a white solid (71.2 mg, 85% yield). Mp 81–83 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.10 (s, 1H), 8.06 (d, *J* = 7.8 Hz, 1H), 7.77–7.79 (m, 1H), 7.57–7.60 (m, 1H), 7.42 (t, *J* = 7.5 Hz, 1H), 7.35 (dt, *J* = 9.5, 3.7 Hz, 3H), 2.46 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  163.4, 150.9, 142.2, 138.9, 132.5, 129.0, 128.3, 127.1, 125.2, 124.9, 124.7, 120.1, 110.7, 21.5. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>14</sub>H<sub>12</sub>NO [M + H]<sup>+</sup>: 210.0919, found: 210.0915.

**2-(3-Fluorophenyl)benzo[d]oxazole (3ae).** Following the general procedure A with **1a** (55.6 mg) and **2e** (65  $\mu$ L), **3ae** was obtained as a white solid (64.0 mg, 75% yield). Mp 91–93 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.05–8.07 (m, 1H), 7.94–7.98 (m, 1H), 7.78–7.80 (m, 1H), 7.59–7.61 (m, 1H), 7.51 (td, *J* = 8.0, 5.6 Hz, 1H), 7.37–7.41 (m, 2H), 7.25 (dt, *J* = 9.1, 1.6 Hz, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  163.0 (d, *J* = 245.3 Hz), 161.9 (d, *J* = 3.8 Hz), 150.9, 142.0, 130.8 (d, *J* = 7.7 Hz), 129.3 (d, *J* = 8.6 Hz), 125.6, 124.9, 123.4 (d, *J* = 2.9 Hz), 120.3, 118.6 (d, *J* = 21.0 Hz), 114.7 (d, *J* = 24.0 Hz), 110.8. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -111.7. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>13</sub>H<sub>9</sub>FNO [M + H]<sup>+</sup>: 214.0668, found: 214.0672.

**2-(*p*-Tolyl)benzo[d]oxazole (3af).** Following the general procedure A with **1a** (55.6 mg) and **2f** (73.3 mg), **3af** was obtained as a white solid (73.5 mg, 88% yield). Mp 115–117 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.15 (d, *J* = 8.3 Hz, 2H), 7.75–7.77 (m, 1H), 7.56–7.58 (m, 1H), 7.32–7.36 (m, 4H), 2.45 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  163.4, 150.8, 142.3, 142.2, 129.8, 127.7, 125.0, 124.6, 124.5, 120.0, 110.6, 21.8. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>14</sub>H<sub>12</sub>NO [M + H]<sup>+</sup>: 210.0919, found: 210.0914.

**2-(4-Fluorophenyl)benzo[d]oxazole (3ag).** Following the general procedure A with **1a** (55.6 mg) and **2g** (65  $\mu$ L), **3ag** was obtained as a white solid (76.1 mg, 89% yield). Mp 97–99 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.25–8.28 (m, 2H), 7.76–7.78 (m, 1H), 7.57–7.59 (m, 1H), 7.35–7.38 (m, 2H), 7.20–7.24 (m, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  164.9 (d, *J* = 250.1 Hz), 162.3, 150.9, 142.2, 129.9 (d, *J* = 9.5 Hz), 125.3, 124.8, 123.6 (d, *J* = 3.9 Hz), 120.1, 116.3 (d, *J* = 22.0 Hz), 110.7. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -107.4. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>13</sub>H<sub>9</sub>FNO [M + H]<sup>+</sup>: 214.0668, found: 214.0660.

**2-(4-Methoxyphenyl)benzo[d]oxazole (3ah).** Following the general procedure A with **1a** (55.6 mg) and **2h** (82.9 mg), **3ah** was obtained as a white solid (87 mg, 97% yield). Mp 102–104 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.20 (dd, *J* = 7.1, 2.1 Hz, 2H), 7.73–7.75 (m, 1H), 7.55–7.57 (m, 1H), 7.31–7.34 (m, 2H), 7.04 (dd, *J* = 6.9, 1.8 Hz, 2H), 3.90 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 163.3, 162.4, 150.8, 142.4, 129.5, 124.7, 124.5, 119.8, 119.7, 114.5, 110.5, 55.6. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>14</sub>H<sub>12</sub>NO<sub>2</sub> [M + H]<sup>+</sup>: 226.0868, found: 226.0864.

**Procedure for the Gram-Scale Synthesis of 3ah.** A mixture of *o*-nitrophenol **1a** (1.0 g, 7.19 mmol), 4-methoxy benzyl alcohol **2h** (1.49 g, 10.79 mmol), **Fe I** (60.17 mg, 2 mol %), and Me<sub>3</sub>NO (21.60 mg, 4 mol %) was placed in a dried 100 mL sealed tube. The tube was degassed and backfilled with argon three times; then, *o*-xylene (18 mL) was added using a syringe under argon flow. The reaction tube was capped, and then the mixture was stirred and heated at 150 °C in an oil bath for 24 h. After completion, the reaction mixture was cooled to room temperature and volatiles were removed under reduced pressure. The residue was purified by silica gel column chromatography using *n*-hexane/ethyl acetate (97/3) as an eluent to afford the corresponding benzoxazole **3ah** (1.18 g, 73% yield) (1.25 g, 77% for 42 h).

**2-(4-Chlorophenyl)benzo[d]oxazole (3ai).** Following the general procedure A with **1a** (55.6 mg) and **2i** (85.5 mg), **3ai** was obtained as a white solid (86.1 mg, 94% yield). Mp 150–152 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.20 (dt, *J* = 8.9, 2.2 Hz, 2H), 7.76–7.79 (m, 1H), 7.58–7.60 (m, 1H), 7.51 (dt, *J* = 9.0, 2.3 Hz, 2H), 7.36–7.39 (m, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 162.2, 150.9, 142.2, 137.9, 129.4, 129.0, 125.8, 125.5, 124.9, 120.2, 110.8. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>13</sub>H<sub>9</sub>ClNO [M + H]<sup>+</sup>: 230.0373, found: 230.0372.

**2-(4-Bromophenyl)benzo[d]oxazole (3aj).** Following the general procedure A with **1a** (55.6 mg) and **2j** (112.3 mg), **3aj** was obtained as a white solid (91.1 mg, 83% yield). Mp 156–158 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.13 (d, *J* = 8.7 Hz, 2H), 7.76–7.79 (m, 1H), 7.68 (dd, *J* = 8.9, 2.1 Hz, 2H), 7.58–7.60 (m, 1H), 7.37 (td, *J* = 3.3, 2.1 Hz, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 162.3, 150.9, 142.1, 132.4, 129.2, 126.4, 126.2, 125.5, 124.9, 120.3, 110.8. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>13</sub>H<sub>9</sub>BrNO [M + H]<sup>+</sup>: 273.9868, found: 273.9858.

**2-(4-Iodophenyl)benzo[d]oxazole (3ak).** Following the general procedure A with **1a** (55.6 mg) and **2k** (140.5 mg), **3ak** was obtained as a white solid (105.2 mg, 82% yield). Mp 168–170 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.96–7.99 (m, 1H), 7.87–7.90 (m, 1H), 7.76–7.78 (m, 1H), 7.57–7.59 (m, 1H), 7.37 (td, *J* = 3.4, 1.8 Hz, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 162.5, 150.9, 142.1, 138.4, 129.1, 126.8, 125.6, 124.9, 120.3, 110.8, 98.6. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>13</sub>H<sub>9</sub>I NO [M + H]<sup>+</sup>: 321.9729, found: 321.9728.

**2-(4-(Trifluoromethyl)phenyl)benzo[d]oxazole (3al).** Following the general procedure A with **1a** (55.6 mg) and **2l** (82 μL), **3al** was obtained as a white solid (83.1 mg, 79% yield). Mp 142–144 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, *J* = 8.2 Hz, 3H), 7.79–7.82 (m, 5H), 7.62 (td, *J* = 3.7, 1.7 Hz, 2H), 7.39–7.42 (m, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 161.6, 151.0, 142.0, 133.1 (*q*, *J* = 32.5 Hz), 130.6, 128.0, 126.1 (*q*, *J* = 3.8 Hz), 125.9, 125.2–119.8 (*q*, *J* = 270.2), 120.5, 110.9. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ –62.9. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>14</sub>H<sub>9</sub>F<sub>3</sub>NO [M + H]<sup>+</sup>: 264.0636, found: 264.0631.

**Methyl 4-(Benzo[d]oxazol-2-yl)benzoate (3am).** Following the general procedure A with **1a** (55.6 mg) and **2m** (99.7 mg), **3am** was obtained as a white solid (61.0 mg, 60% yield). Mp 193–195 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.33–8.35 (m, 2H), 8.20 (d, *J* = 8.7 Hz, 2H), 7.80–7.82 (m, 1H), 7.61–7.63 (m, 1H), 7.40 (dd, *J* = 6.1, 2.6 Hz, 2H), 3.97 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 166.5, 162.1, 151.0, 142.1, 132.7, 131.8, 130.3, 127.6, 125.9, 125.0, 120.5, 110.9, 52.6. IR (neat) *v* 3072, 1718, 1540, 1456, 1260, 1108 cm<sup>-1</sup>. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>15</sub>H<sub>12</sub>NO<sub>3</sub> [M + H]<sup>+</sup>: 254.0814, found: 254.0817.

**4-(Benzo[d]oxazol-2-yl)benzotrile (3an).** Following the general procedure A with **1a** (55.6 mg) and **2n** (79.9 mg), **3an** was obtained as

a white solid (45.1 mg, 51% yield). Mp 203–205 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.34 (dd, *J* = 6.9, 1.8 Hz, 2H), 7.79–7.81 (m, 3H), 7.60 (*q*, *J* = 3.1 Hz, 1H), 7.39–7.43 (m, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 161.0, 151.0, 142.0, 132.8, 131.2, 128.0, 126.3, 125.2, 120.7, 118.3, 114.8, 111.0. IR (neat) *v* 3065, 2308, 1652, 1507, 1216, 750, 689, 669 cm<sup>-1</sup>. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>14</sub>H<sub>9</sub>N<sub>2</sub>O [M + H]<sup>+</sup>: 221.0715, found: 221.0716.

**2-(Benzo[d][1,3]dioxol-5-yl)benzo[d]oxazole (3ao).** Following the general procedure A with **1a** (55.6 mg) and **2o** (91.3 mg), **3ao** was obtained as a white solid (83.1 mg, 87% yield). Mp 150–152 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.72–7.74 (m, 1H), 7.70 (d, *J* = 1.4 Hz, 1H), 7.54–7.56 (m, 1H), 7.32–7.34 (m, 2H), 6.94 (d, *J* = 8.2 Hz, 1H), 6.07 (s, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 163.0, 150.8, 150.7, 148.4, 142.3, 124.9, 124.7, 123.0, 121.3, 119.9, 110.6, 108.9, 107.8, 101.9. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>14</sub>H<sub>10</sub>NO<sub>3</sub> [M + H]<sup>+</sup>: 240.0661, found: 240.0658.

**2-(Naphthalen-2-yl)benzo[d]oxazole (3ap).** Following the general procedure A with **1a** (55.6 mg) and **2p** (94.9 mg), **3ap** was obtained as a white solid (79.3 mg, 81% yield). Mp 111–113 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.79 (s, 1H), 8.33 (dd, *J* = 8.7, 1.4 Hz, 1H), 7.99 (*q*, *J* = 4.3 Hz, 2H), 7.91 (*q*, *J* = 3.0 Hz, 1H), 7.82 (*q*, *J* = 3.0 Hz, 1H), 7.57–7.65 (m, 3H), 7.39 (*q*, *J* = 3.2 Hz, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 163.4, 151.0, 142.4, 134.9, 133.1, 129.1, 128.9, 128.3, 128.7, 128.0, 127.7, 125.3, 124.8, 124.5, 124.1, 120.2, 110.8. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>17</sub>H<sub>12</sub>NO [M + H]<sup>+</sup>: 246.0919, found: 246.0916.

**2-(Furan-2-yl)benzo[d]oxazole (3aq).** Following the general procedure A with **1a** (55.6 mg) and **2q** (52 μL), **3aq** was obtained as a white solid (37.2 mg, 50% yield). Mp 87–89 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.75–7.77 (m, 1H), 7.67 (s, 1H), 7.55–7.57 (m, 1H), 7.36 (dt, *J* = 7.0, 2.2 Hz, 2H), 7.28 (t, *J* = 2.5 Hz, 1H), 7.26 (d, *J* = 2.3 Hz, 1H), 6.61–6.63 (m, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 155.4, 150.3, 145.9, 142.7, 141.8, 125.4, 125.0, 120.3, 114.4, 112.4, 110.7. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>11</sub>H<sub>8</sub>NO<sub>2</sub> [M + H]<sup>+</sup>: 186.0555, found: 186.0561.

**2-(Thiophen-2-yl)benzo[d]oxazole (3ar).** Following the general procedure A with **1a** (55.6 mg) and **2r** (57 μL), **3ar** was obtained as a white solid (64.2 mg, 80% yield). Mp 104–106 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.92 (*q*, *J* = 1.7 Hz, 1H), 7.73–7.75 (m, 1H), 7.54–7.57 (m, 2H), 7.33–7.36 (m, 2H), 7.20 (dd, *J* = 4.8, 3.9 Hz, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 159.2, 150.6, 142.1, 130.4, 130.1, 129.8, 128.4, 125.2, 124.9, 119.9, 110.6. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>11</sub>H<sub>8</sub>NOS [M + H]<sup>+</sup>: 202.0327, found: 202.0326.

**2-(Pyridin-3-yl)benzo[d]oxazole (3as).** Following the general procedure A with **1a** (55.6 mg) and **2s** (58 μL), **3as** was obtained as a white solid (68.2 mg, 87% yield). Mp 112–114 °C. Eluent: *n*-hexane/ethyl acetate (90/10). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.48 (d, *J* = 0.9 Hz, 1H), 8.77 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.52 (dt, *J* = 7.9, 1.9 Hz, 1H), 7.80–7.82 (m, 1H), 7.61–7.64 (m, 1H), 7.48 (ddd, *J* = 8.0, 4.8, 0.9 Hz, 1H), 7.39–7.43 (m, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 160.8, 152.2, 150.8, 148.9, 141.9, 134.8, 125.8, 125.0, 123.8, 123.6, 120.4, 110.9. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>12</sub>H<sub>9</sub>N<sub>2</sub>O [M + H]<sup>+</sup>: 197.0715, found: 197.0716.

**2-Styrylbenzo[d]oxazole (3at).** Following the general procedure A with **1a** (55.6 mg) and **2t** (80.5 mg), **3at** was obtained as a white solid (27.8 mg, 31% yield). Mp 83–85 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80 (d, *J* = 16.5 Hz, 1H), 7.72 (*q*, *J* = 3.1 Hz, 1H), 7.60–7.62 (m, 2H), 7.52–7.55 (m, 1H), 7.38–7.45 (m, 3H), 7.34 (td, *J* = 3.5, 1.8 Hz, 2H), 7.09 (d, *J* = 16.5 Hz, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 162.9, 150.6, 142.3, 139.6, 135.3, 129.9, 129.1, 127.7, 125.4, 124.7, 120.0, 114.1, 110.5. HRMS (FAB<sup>+</sup>) *m/z* calcd for C<sub>15</sub>H<sub>12</sub>NO [M + H]<sup>+</sup>: 222.0919, found: 222.0924.

**2-Cyclohexylbenzo[d]oxazole (3au).** Following the general procedure A with **1a** (55.6 mg) and **2u** (74 μL), **3au** was obtained as a white solid (23.2 mg, 29% yield). Mp 37–39 °C. Eluent: *n*-hexane/ethyl acetate (97/3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.67–7.69 (m, 1H), 7.46–7.49 (m, 1H), 7.26–7.31 (m, 2H), 2.95 (qd, *J* =

7.5, 3.8 Hz, 1H), 2.15–2.19 (m, 2H), 1.87 (dt,  $J = 12.7$ , 3.6 Hz, 2H), 1.67–1.76 (m, 3H), 1.25–1.49 (m, 3H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  170.6, 150.7, 141.4, 124.5, 124.1, 119.8, 110.4, 38.1, 30.6, 25.9, 25.8. HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{13}\text{H}_{16}\text{NO}$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 202.1232, found: 202.1235.

**6-Methyl-2-phenylbenzo[d]oxazole (3ba).** Following the general procedure A with **1b** (61.3 mg) and **2a** (62  $\mu\text{L}$ ), **3ba** was obtained as a white solid (75.3 mg, 90% yield). Mp 93–95 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.24 (td,  $J = 4.0$ , 1.6 Hz, 2H), 7.64 (d,  $J = 7.9$  Hz, 1H), 7.51 (q,  $J = 3.3$  Hz, 3H), 7.38 (s, 1H), 7.15–7.18 (m, 1H), 2.50 (s, 3H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  162.7, 151.2, 140.0, 135.7, 131.4, 129.0, 127.6, 127.5, 125.9, 119.5, 110.9, 21.9. HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{14}\text{H}_{12}\text{NO}$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 210.0919, found: 210.0920.

**6-Fluoro-2-phenylbenzo[d]oxazole (3ca).** Following the general procedure A with **1c** (62.8 mg) and **2a** (62  $\mu\text{L}$ ), **3ca** was obtained as a white solid (66.7 mg, 78% yield). m.p 109–111 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.21–8.24 (m, 2H), 7.70 (q,  $J = 4.6$  Hz, 1H), 7.52–7.56 (m, 3H), 7.32 (dd,  $J = 7.8$ , 2.3 Hz, 1H), 7.08–7.14 (m, 1H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  163.6 (d,  $J = 2.9$  Hz), 160.8 (d,  $J = 242.5$  Hz), 150.8 (d,  $J = 14.3$  Hz), 138.6, 131.8, 129.1, 127.6, 127.0, 120.4 (d,  $J = 9.5$  Hz), 112.7 (d,  $J = 24.8$  Hz), 98.8 (d,  $J = 27.7$  Hz).  $^{19}\text{F}$  NMR (376 MHz,  $\text{CDCl}_3$ )  $\delta$  –115.0. HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{13}\text{H}_9\text{FNO}$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 214.0668, found: 214.0670.

**5-Methyl-2-phenylbenzo[d]oxazole (3da).** Following the general procedure A with **1d** (61.3 mg) and **2a** (62  $\mu\text{L}$ ), **3da** was obtained as a white solid (74.6 mg, 89% yield). Mp 101–103 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.23–8.26 (m, 2H), 7.56 (s, 1H), 7.50–7.53 (m, 3H), 7.45 (d,  $J = 7.9$  Hz, 1H), 7.16 (dd,  $J = 8.6$ , 1.2 Hz, 1H), 2.49 (s, 3H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  163.2, 149.1, 142.4, 134.5, 131.5, 129.0, 127.7, 127.5, 126.3, 120.0, 110.0, 21.6. HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{14}\text{H}_{12}\text{NO}$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 210.0919, found: 210.0918.

**5-Fluoro-2-phenylbenzo[d]oxazole (3ea).** Following the general procedure A with **1e** (62.8 mg) and **2a** (62  $\mu\text{L}$ ), **3ea** was obtained as a white solid (51.8 mg, 61% yield). m.p 104–106 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.24 (dd,  $J = 7.6$ , 2.1 Hz, 2H), 7.50–7.56 (m, 4H), 7.45 (dd,  $J = 8.6$ , 2.4 Hz, 1H), 7.09 (td,  $J = 9.2$ , 2.4 Hz, 1H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  164.9, 160.3 (d,  $J = 237.7$  Hz), 147.2, 143.1 (d,  $J = 13.4$  Hz), 132.0, 129.1, 127.8, 127.1 (d,  $J = 12.4$  Hz), 112.9 (d,  $J = 25.8$  Hz), 111.0 (d,  $J = 10.5$  Hz), 106.6 (d,  $J = 24.8$  Hz).  $^{19}\text{F}$  NMR (376 MHz,  $\text{CDCl}_3$ )  $\delta$  –117.6. HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{13}\text{H}_9\text{FNO}$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 214.0668, found: 214.0667.

**4-Methyl-2-phenylbenzo[d]oxazole (3fa).** Following the general procedure A with **1f** (61.3 mg) and **2a** (62  $\mu\text{L}$ ), **3fa** was obtained as a white solid (70.3 mg, 84% yield). Mp 90–92 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.29–8.31 (m, 2H), 7.53–7.56 (m, 3H), 7.43 (d,  $J = 7.9$  Hz, 1H), 7.26 (t,  $J = 7.6$  Hz, 1H), 7.17 (d,  $J = 8.6$  Hz, 1H), 2.71 (s, 3H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  162.4, 150.7, 141.6, 131.4, 130.741, 128.944, 127.741, 127.6, 125.2, 124.9, 108.0, 16.7. HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{14}\text{H}_{12}\text{NO}$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 210.0919, found: 210.0922.

**7-Methyl-2-phenylbenzo[d]oxazole (3ga).** Following the general procedure A with **1g** (61.3 mg) and **2a** (62  $\mu\text{L}$ ), **3ga** was obtained as a yellow solid (63.4 mg, 76% yield). Mp 88–90 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.27–8.29 (m, 2H), 7.60 (d,  $J = 7.9$  Hz, 1H), 7.54 (q,  $J = 2.4$  Hz, 3H), 7.24–7.27 (m, 2H), 7.15 (d,  $J = 7.3$  Hz, 1H), 2.60 (s, 3H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  162.9, 150.2, 141.8, 131.6, 129.0, 127.7, 127.5, 126.3, 124.6, 121.3, 117.5, 15.4. HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{14}\text{H}_{12}\text{NO}$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 210.0919, found: 210.0922.

**5-Bromo-7-fluoro-2-phenylbenzo[d]oxazole (3ha).** Following the general procedure A with **1h** (94.4 mg) and **2a** (62  $\mu\text{L}$ ), **3ha** was obtained as a white solid (52.4 mg, 45% yield). m.p 157–159 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.26 (d,  $J = 6.7$  Hz, 2H), 7.71 (s, 1H), 7.53–7.59 (m, 3H), 7.27–7.30 (m, 1H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  164.8, 148.0, 145.9 (d,  $J = 104.4$  Hz), 137.4, 132.5, 129.2, 128.2, 126.2, 119.2 (d,  $J = 11.0$  Hz),

116.7 (d,  $J = 6.7$  Hz), 115.8 (d,  $J = 19.1$  Hz).  $^{19}\text{F}$  NMR (376 MHz,  $\text{CDCl}_3$ )  $\delta$  –131.6. HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{13}\text{H}_8\text{BrFNO}$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 291.9773, found: 291.9777.

**2-Phenylnaphtho[2,1-d]oxazole (3ia).** Following the general procedure A with **1i** (75.7 mg) and **2a** (62  $\mu\text{L}$ ), **3ia** was obtained as a white solid (53.9 mg, 55% yield). m.p 122–124 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.31–8.36 (m, 3H), 7.99 (d,  $J = 8.6$  Hz, 1H), 7.86 (d,  $J = 8.6$  Hz, 1H), 7.80 (d,  $J = 8.6$  Hz, 1H), 7.66 (t,  $J = 7.4$  Hz, 1H), 7.53–7.58 (m, 4H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  162.6, 146.6, 138.8, 131.9, 131.3, 129.1, 128.9, 127.6, 127.5, 127.0, 125.8, 125.6, 120.5, 120.3, 118.8. HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{17}\text{H}_{12}\text{NO}$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 246.0919, found: 246.0915.

**2-Phenylbenzo[d]oxazole-5-carbonitrile (3ja).** Following the general procedure A with **1j** (65.7 mg) and **2a** (62  $\mu\text{L}$ ), **3ja** was obtained as a white solid (52.7 mg, 60% yield). m.p 196–198 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.25–8.27 (m, 2H), 8.08 (s, 1H), 7.66–7.69 (m, 2H), 7.54–7.61 (m, 3H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  165.2, 153.2, 142.7, 132.6, 129.2, 129.2, 128.1, 126.1, 124.6, 118.9, 111.9, 108.6. IR (neat)  $\nu$  3062, 2224, 1619, 1551, 1261, 788, 705, 689  $\text{cm}^{-1}$ . HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{14}\text{H}_9\text{N}_2\text{O}$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 221.0715, found: 221.0713.

**1-(2-Phenylbenzo[d]oxazol-5-yl)ethan-1-one (3ka).** Following the general procedure A with **1k** (72.5 mg) and **2a** (62  $\mu\text{L}$ ), **3ka** was obtained as a white solid (19.7 mg, 21% yield). Mp 145–147 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.38 (d,  $J = 0.9$  Hz, 1H), 8.27 (dd,  $J = 7.8$ , 1.8 Hz, 2H), 8.06 (dd,  $J = 8.7$ , 1.8 Hz, 1H), 7.64 (d,  $J = 8.7$  Hz, 1H), 7.55–7.57 (m, 3H), 2.70 (s, 3H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  197.3, 164.7, 153.9, 142.5, 134.6, 132.2, 129.2, 128.0, 126.7, 126.0, 121.1, 110.8, 26.9. IR (neat)  $\nu$  3067, 2920, 1675, 814, 722, 688  $\text{cm}^{-1}$ . HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{15}\text{H}_{12}\text{NO}_2$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 238.0868, found: 238.0861.

**Synthesis of Benzothiazoles. Preparation of *o*-Nitrothiophenol 4a.**<sup>15</sup> To a suspension of *o*-nitrophenyl disulfide (1 g, 3.25 mmol) in 25 mL of dry tetrahydrofuran (THF),  $\text{PPh}_3$  (1.28 g, 4.88 mmol), 2-mercaptoethanol (0.23 mL, 3.25 mmol), and  $\text{H}_2\text{O}$  (0.6 mL, 32.5 mmol) were added. The solution was stirred at 50 °C for 8 h, then cooled to rt. The mixture was concentrated, redissolved in dichloromethane (DCM), washed with brine, dried over  $\text{Na}_2\text{SO}_4$ , and evaporated. The resulting orange oil was purified by silica gel column chromatography using *n*-hexane/ethyl acetate (90/10) as an eluent to afford the bright-yellow solid **4a** (834 mg, 83% yield).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.26 (d,  $J = 8.2$  Hz, 1H), 7.44 (dd,  $J = 4.8$ , 1.1 Hz, 2H), 7.27–7.31 (m, 1H), 4.02 (s, 1H).

**General Procedure B.** To a predried 10 mL sealed tube, *o*-nitrothiophenol **4a** (0.4 mmol, 1.0 equiv), alcohol **2** (0.6 mmol, 1.5 equiv), **Fe 1** (3.35 mg, 0.008 mmol),  $\text{Me}_3\text{NO}$  (1.2 mg, 0.016 mmol), and  $\text{tBuONa}$  (38.50 mg, 0.4 mmol, 1.0 equiv) were added. The tube was degassed and backfilled with argon three times; then, *o*-xylene (1 mL) was added using a syringe under argon flow. The reaction tube was capped, and then the mixture was stirred and heated at 150 °C in an oil bath for 24 h. After completion, the reaction mixture was cooled to room temperature and volatiles were removed under reduced pressure. The residue was purified by silica gel column chromatography using *n*-hexane/ethyl acetate as an eluent to afford the desired benzothiazole derivatives **5**.

**2-Phenylbenzo[d]thiazole (5aa).** Following the general procedure B with **4a** (62.1 mg) and **2a** (62  $\mu\text{L}$ ), **5aa** was obtained as a white solid (60.2 mg, 71% yield). Mp 114–116 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.07–8.12 (m, 3H), 7.91–7.93 (m, 1H), 7.48–7.52 (m, 4H), 7.37–7.42 (m, 1H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  168.2, 154.3, 135.2, 133.7, 131.1, 129.1, 127.8, 126.4, 125.3, 123.4, 121.7. HRMS (FAB<sup>+</sup>)  $m/z$  calcd for  $\text{C}_{13}\text{H}_{10}\text{NS}$  [ $\text{M} + \text{H}$ ]<sup>+</sup>: 212.0534, found: 212.0538.

**2-(Pyridin-3-yl)benzo[d]thiazole (5as).** Following the general procedure B with **4a** (62.1 mg) and **2s** (58  $\mu\text{L}$ ), **5as** was obtained as a white solid (52.1 mg, 61% yield). Mp 129–131 °C. Eluent: *n*-hexane/ethyl acetate (90/10).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.30 (d,  $J = 1.8$  Hz, 1H), 8.73 (q,  $J = 2.0$  Hz, 1H), 8.40 (td,  $J = 5.1$ , 2.7 Hz, 1H), 8.11 (d,  $J = 8.6$  Hz, 1H), 7.95 (d,  $J = 8.0$  Hz, 1H), 7.52–7.56 (m, 1H),

7.42–7.47 (m, 2H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  164.7, 154.1, 151.8, 148.8, 135.1, 134.7, 129.8, 126.8, 125.9, 123.9, 123.6, 121.9. HRMS ( $\text{FAB}^+$ )  $m/z$  calcd for  $\text{C}_{12}\text{H}_9\text{N}_2\text{S}$  [ $\text{M} + \text{H}$ ] $^+$ : 213.0486, found: 213.0490.

**2-(Naphthalen-1-yl)benzo[d]thiazole (5av).** Following the general procedure B with **4a** (62.1 mg) and **2v** (94.9 mg), **5av** was obtained as a white solid (75.0 mg, 72% yield). Mp 126–128 °C. Eluent: *n*-hexane/ethyl acetate (97/3).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.93 (d,  $J$  = 8.6 Hz, 1H), 8.20 (d,  $J$  = 8.0 Hz, 1H), 7.93–8.01 (m, 4H), 7.54–7.65 (m, 4H), 7.44–7.48 (m, 1H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.8, 154.3, 135.6, 134.2, 131.2, 131.0, 130.8, 129.5, 128.6, 127.8, 126.7, 126.4, 126.0, 125.4, 125.1, 123.7, 121.6. HRMS ( $\text{FAB}^+$ )  $m/z$  calcd for  $\text{C}_{17}\text{H}_{12}\text{NS}$  [ $\text{M} + \text{H}$ ] $^+$ : 262.0690, found: 262.0692.

**Synthesis of Benzimidazoles. General Procedure C.** A 10 mL sealed tube was charged with *o*-nitroaniline **6a** (0.4 mmol, 1.0 equiv), alcohol **2** (0.6 mmol, 1.5 equiv), **Fe 1** (3.35 mg, 0.008 mmol),  $\text{Me}_3\text{NO}$  (1.2 mg, 0.016 mmol), and  $^t\text{BuONa}$  (57.66 mg, 0.6 mmol, 1.5 equiv). The tube was degassed and backfilled with argon three times; then, chlorobenzene (1 mL) was added using a syringe under argon flow. The reaction tube was capped, and then the mixture was stirred and heated at 150 °C in an oil bath for 42 h. After completion, the reaction mixture was cooled to room temperature and volatiles were removed under reduced pressure. The resulting residue was purified by silica gel column chromatography using *n*-hexane/ethyl acetate or dichloromethane/methanol as an eluent to provide the desired benzimidazoles **7**.

**2-Phenyl-1H-benzo[d]imidazole (7aa).** Following the general procedure C with **6a** (55.3 mg) and **2a** (62  $\mu\text{L}$ ), **7aa** was obtained as a white solid (62.4 mg, 80% yield). Mp 291–293 °C. Eluent: *n*-hexane/ethyl acetate (4/1).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.90 (s, 1H), 8.17 (d,  $J$  = 6.9 Hz, 2H), 7.47–7.59 (m, 5H), 7.20 (td,  $J$  = 6.5, 3.8 Hz, 2H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta$  151.2, 130.2, 129.8, 129.0, 126.5, 122.1. HRMS ( $\text{FAB}^+$ )  $m/z$  calcd for  $\text{C}_{13}\text{H}_{11}\text{N}_2$  [ $\text{M} + \text{H}$ ] $^+$ : 195.0922, found: 195.0924.

**2-(*p*-Tolyl)-1H-benzo[d]imidazole (7af).** Following the general procedure C with **6a** (55.3 mg) and **2f** (73.3 mg), **7af** was obtained as a white solid (66.5 mg, 80% yield). Mp 265–267 °C. Eluent: *n*-hexane/ethyl acetate (4/1).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.82 (s, 1H), 8.07 (d,  $J$  = 7.9 Hz, 2H), 7.64 (d,  $J$  = 7.3 Hz, 1H), 7.51 (d,  $J$  = 7.3 Hz, 1H), 7.36 (d,  $J$  = 7.9 Hz, 2H), 7.19 (dd,  $J$  = 8.7, 6.0 Hz, 2H), 2.38 (s, 3H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta$  151.4, 143.8, 139.6, 135.0, 129.5, 127.5, 126.4, 122.4, 121.6, 118.7, 111.2, 21.0. HRMS ( $\text{FAB}^+$ )  $m/z$  calcd for  $\text{C}_{14}\text{H}_{13}\text{N}_2$  [ $\text{M} + \text{H}$ ] $^+$ : 209.1079, found: 209.1076.

**2-(4-Fluorophenyl)-1H-benzo[d]imidazole (7ag).** Following the general procedure C with **6a** (55.3 mg) and **2g** (65  $\mu\text{L}$ ), **7ag** was obtained as a white solid (67.4 mg, 79% yield). Mp 250–252 °C. Eluent: *n*-hexane/ethyl acetate (4/1).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.90 (s, 1H), 8.22 (td,  $J$  = 6.1, 2.2 Hz, 2H), 7.65 (d,  $J$  = 7.4 Hz, 1H), 7.52 (d,  $J$  = 7.4 Hz, 1H), 7.37–7.42 (m, 2H), 7.20 (dd,  $J$  = 8.4, 6.3 Hz, 2H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta$  163.2 (d,  $J$  = 246.3 Hz), 150.6, 128.8 (d,  $J$  = 8.6 Hz), 126.8 (d,  $J$  = 2.9 Hz), 122.4, 116.2 (d,  $J$  = 22.3 Hz).  $^{19}\text{F}$  NMR (376 MHz,  $\text{DMSO}-d_6$ )  $\delta$  –111.1. HRMS ( $\text{FAB}^+$ )  $m/z$  calcd for  $\text{C}_{13}\text{H}_{10}\text{N}_2\text{F}$  [ $\text{M} + \text{H}$ ] $^+$ : 213.0828, found: 213.0828.

**2-(4-Methoxyphenyl)-1H-benzo[d]imidazole (7ah).** Following the general procedure C with **6a** (55.3 mg) and **2h** (82.9 mg), **7ah** was obtained as a white solid (76.1 mg, 85% yield). Mp 225–227 °C. Eluent: *n*-hexane/ethyl acetate (4/1).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.75 (s, 1H), 8.12 (d,  $J$  = 8.6 Hz, 2H), 7.62 (d,  $J$  = 6.7 Hz, 1H), 7.49 (d,  $J$  = 6.7 Hz, 1H), 7.17 (d,  $J$  = 4.9 Hz, 2H), 7.11 (d,  $J$  = 8.6 Hz, 2H), 3.84 (s, 3H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta$  160.6, 151.4, 143.940, 135.0, 128.0, 122.7, 122.1, 121.5, 118.5, 114.4, 111.1, 55.4. HRMS ( $\text{FAB}^+$ )  $m/z$  calcd for  $\text{C}_{14}\text{H}_{13}\text{N}_2\text{O}$  [ $\text{M} + \text{H}$ ] $^+$ : 225.1028, found: 225.1027.

**2-(4-Bromophenyl)-1H-benzo[d]imidazole (7aj).** Following the general procedure C with **6a** (55.3 mg) and **2j** (112.3 mg), **7aj** was obtained as a white solid (69.2 mg, 63% yield). Mp 277–279 °C. Eluent: *n*-hexane/ethyl acetate (4/1).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.99 (s, 1H), 8.12 (dt,  $J$  = 9.0, 2.1 Hz, 2H), 7.76–7.79 (m, 2H),

7.60 (s, 2H), 7.22 (td,  $J$  = 6.4, 3.5 Hz, 2H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta$  150.2, 132.0, 129.4, 128.4, 123.3, 122.5. HRMS ( $\text{FAB}^+$ )  $m/z$  calcd for  $\text{C}_{13}\text{H}_{10}\text{BrN}_2$  [ $\text{M} + \text{H}$ ] $^+$ : 273.0027, found: 273.0024.

**2-(Benzo[d][1,3]dioxol-5-yl)-1H-benzo[d]imidazole (7ao).** Following the general procedure C with **6a** (55.3 mg) and **2o** (91.3 mg), **7ao** was obtained as a white solid (67.6 mg, 71% yield). Mp 250–252 °C. Eluent: *n*-hexane/ethyl acetate (4/1).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.73 (s, 1H), 7.71 (td,  $J$  = 8.9, 1.4 Hz, 2H), 7.62 (d,  $J$  = 6.7 Hz, 1H), 7.49 (d,  $J$  = 6.7 Hz, 1H), 7.18 (q,  $J$  = 4.5 Hz, 2H), 7.09 (d,  $J$  = 8.0 Hz, 1H), 6.12 (s, 2H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta$  151.1, 148.7, 147.9, 143.7, 134.9, 124.3, 122.3, 121.56, 120.9, 118.6, 111.1, 108.8, 106.5, 101.6. HRMS ( $\text{FAB}^+$ )  $m/z$  calcd for  $\text{C}_{14}\text{H}_{11}\text{N}_2\text{O}_2$  [ $\text{M} + \text{H}$ ] $^+$ : 239.0821, found: 239.0815.

**2-(Thiophen-2-yl)-1H-benzo[d]imidazole (7ar).** Following the general procedure C with **6a** (55.3 mg) and **2r** (57  $\mu\text{L}$ ), **7ar** was obtained as a white solid (47.3 mg, 59% yield). Mp 280–282 °C. Eluent: *n*-hexane/ethyl acetate (4/1).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.93 (s, 1H), 7.83 (d,  $J$  = 3.7 Hz, 1H), 7.72 (d,  $J$  = 4.3 Hz, 1H), 7.54 (s, 2H), 7.19–7.24 (m, 3H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta$  147.0, 133.7, 128.8, 128.3, 126.7, 122.6, 121.8, 118.5, 111.1. HRMS ( $\text{FAB}^+$ )  $m/z$  calcd for  $\text{C}_{11}\text{H}_9\text{N}_2\text{S}$  [ $\text{M} + \text{H}$ ] $^+$ : 201.0486, found: 201.0484.

**2-(Pyridin-3-yl)-1H-benzo[d]imidazole (7as).** Following the general procedure C with **6a** (55.3 mg) and **2s** (58  $\mu\text{L}$ ), **7as** was obtained as a white solid (49.4 mg, 63% yield). Mp 254–256 °C. Eluent: dichloromethane/methanol (98/2).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  13.10 (s, 1H), 9.35 (d,  $J$  = 1.8 Hz, 1H), 8.67 (dd,  $J$  = 4.9, 1.2 Hz, 1H), 8.49 (dt,  $J$  = 7.9, 1.8 Hz, 1H), 7.57–7.72 (m, 3H), 7.24 (d,  $J$  = 4.3 Hz, 2H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta$  150.5, 148.9, 147.5, 143.7, 135.0, 133.8, 126.2, 124.0, 123.0, 122.0, 119.1, 111.512. HRMS ( $\text{FAB}^+$ )  $m/z$  calcd for  $\text{C}_{12}\text{H}_{10}\text{N}_3$  [ $\text{M} + \text{H}$ ] $^+$ : 196.0875, found: 196.0874.

**2-(Naphthalen-1-yl)-1H-benzo[d]imidazole (7av).** Following the general procedure C with **6a** (55.3 mg) and **2v** (94.9 mg), **7av** was obtained as a white solid (75.1 mg, 77% yield). Mp 254–256 °C. Eluent: *n*-hexane/ethyl acetate (4/1).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.94 (s, 1H), 9.11 (d,  $J$  = 8.6 Hz, 1H), 8.01–8.11 (m, 3H), 7.79 (d,  $J$  = 6.7 Hz, 1H), 7.58–7.71 (m, 4H), 7.27 (s, 2H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta$  151.4, 143.940, 134.5, 133.6, 130.5, 130.2, 128.4, 127.9, 127.5, 127.1, 126.4, 125.3, 122.7, 121.6, 119.1, 111.4. HRMS ( $\text{FAB}^+$ )  $m/z$  calcd for  $\text{C}_{17}\text{H}_{13}\text{N}_2$  [ $\text{M} + \text{H}$ ] $^+$ : 245.1079, found: 245.1081.

**Experimental Procedure for the Reaction of Secondary Alcohol 2w with 1a.** A mixture of *o*-nitrophenol **1a** (55.6 mg, 0.4 mmol), benzhydrol **2w** (110.5 mg, 0.6 mmol), **Fe 1** (3.35 mg, 0.008 mmol), and  $\text{Me}_3\text{NO}$  (1.20 mg, 0.016 mmol) was placed in a dried 10 mL sealed tube. The tube was degassed and backfilled with argon three times; then, *o*-xylene (1.0 mL) was added using a syringe under argon flow. The reaction tube was capped, and then the mixture was stirred and heated at 150 °C in an oil bath for 24 h. After completion, the reaction mixture was cooled to room temperature and volatiles were removed under reduced pressure. The residue was purified by silica gel column chromatography using *n*-hexane/ethyl acetate (5–25%) as an eluent to afford *o*-aminophenol **1a'** (10.0 mg, 23% yield based on **1a**) and benzophenone **2w'** (59.1 mg, 54% yield based on **2w**).

**2-Aminophenol (1a').**<sup>16</sup> Brown solid. Eluent: *n*-hexane/ethyl acetate (75/25).  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  8.90 (s, 1H), 6.62 (d,  $J$  = 8.0 Hz, 1H), 6.50–6.58 (m, 2H), 6.37 (td,  $J$  = 7.4, 1.2 Hz, 1H), 4.44 (s, 2H).

**Benzophenone (2w').**<sup>17</sup> White solid. Eluent: *n*-hexane/ethyl acetate (95/5).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.80–7.82 (m, 4H), 7.57–7.61 (m, 2H), 7.49 (t,  $J$  = 7.6 Hz, 4H).

## ■ ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.joc.0c02191>.

$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra and results of catalyst screening (PDF)



## AUTHOR INFORMATION

### Corresponding Author

**Suckchang Hong** – Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea; [orcid.org/0000-0003-4975-9192](https://orcid.org/0000-0003-4975-9192); Email: [schong17@snu.ac.kr](mailto:schong17@snu.ac.kr)

### Authors

**Ramachandra Reddy Putta** – BK 21 Plus Project, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea

**Simin Chun** – Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea

**Seung Hyun Choi** – Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea

**Seok Beom Lee** – Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea

**Dong-Chan Oh** – Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea; [orcid.org/0000-0001-6405-5535](https://orcid.org/0000-0001-6405-5535)

Complete contact information is available at:  
<https://pubs.acs.org/10.1021/acs.joc.0c02191>

### Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (2018R1C1B6005607 and 2018R1A4A1021703) and Creative-Pioneering Researchers Program through Seoul National University (SNU).

## REFERENCES

(1) (a) Matsumura, K.; Ono, M.; Kitada, A.; Watanabe, H.; Yoshimura, M.; Iikuni, S.; Kimura, H.; Okamoto, Y.; Ihara, M.; Saji, H. Structure–Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimer's Disease Brains. *J. Med. Chem.* **2015**, *58*, 7241–7257. (b) Potashman, M.-H.; Bready, J.; Coxon, A.; DeMelfi, T. M.; DiPietro, L.; Doerr, N.; Elbaum, D.; Estrada, J.; Gallant, P.; Germain, J.; Gu, Y. Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors. *J. Med. Chem.* **2007**, *50*, 4351–4373. (c) Sun, Q.; Wu, R.; Cai, S.; Lin, Y.; Sellers, L.; Sakamoto, K.; He, B.; Peterson, B. R. Synthesis and Biological Evaluation of Analogues of AKT (Protein Kinase B) Inhibitor-IV. *J. Med. Chem.* **2011**, *54*, 1126–1139. (d) Mortimer, C. G.; Wells, G.; Crochard, J. P.; Stone, E. L.; Bradshaw, T. D.; Stevens, M. F.; Westwell, A. D. Antitumor Benzothiazoles. 26. 2-(3, 4-Dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a Simple Fluorinated 2-Arylbenzothiazole, Shows Potent and Selective Inhibitory Activity against Lung, Colon, and Breast Cancer Cell Lines. *J. Med. Chem.* **2006**, *49*, 179–185. (e) Aiello, S.; Wells, G.; Stone, E. L.; Kadri, H.; Bazzi, R.; Bell, D. R.; Stevens, M. F.; Matthews, C. S.; Bradshaw, T. D.; Westwell, A. D. Synthesis and Biological Properties of Benzothiazole, Benzoxazole, and

Chromen-4-one Analogues of the Potent Antitumor Agent 2-(3, 4-Dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). *J. Med. Chem.* **2008**, *51*, 5135–5139. (f) Boyer, J.; Arnoult, E.; Me'debielle, M.; Guillemont, J.; Unge, J.; Jochmans, D. Difluoromethylbenzoxazole Pyrimidine Thioether Derivatives: A Novel Class of Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. *J. Med. Chem.* **2011**, *54*, 7974–7985. (g) Bansal, Y.; Silakari, O. The therapeutic journey of benzimidazoles: A review. *Bioorg. Med. Chem.* **2012**, *20*, 6208–6236. (h) Kumar, D.; Jacob, M. R.; Reynolds, M. B.; Kerwin, S. M. Synthesis and Evaluation of Anticancer Benzoxazoles and Benzimidazoles Related to UK-1. *Bioorg. Med. Chem.* **2002**, *10*, 3997–4004. (i) Tahlan, S.; Kumar, S.; Ramasamy, K.; Lim, S. M.; Shah, S. A. A.; Mani, V.; Narasimhan, B. Design, synthesis and biological profile of heterocyclic benzimidazole analogues as prospective antimicrobial and antiproliferative agents. *BMC Chem.* **2019**, *13*, 50.

(2) (a) Wu, Y.; Peng, X.; Fan, J.; Gao, S.; Tian, M.; Zhao, J.; Sun, S. Fluorescence Sensing of Anions Based on Inhibition of Excited-State Intramolecular Proton Transfer. *J. Org. Chem.* **2007**, *72*, 62–70. (b) Meesala, Y.; Kavala, V.; Chang, H. C.; Kuo, T. S.; Yao, C. F.; Lee, W. Z. Synthesis, structures and electrochemical and photophysical properties of anilido-benzoxazole boron difluoride (ABB) complexes. *Dalton Trans.* **2015**, *44*, 1120–1129. (c) Tanaka, K.; Kumagai, T.; Aoki, H.; Deguchi, M.; Iwata, S. Application of 2-(3,5,6-Trifluoro-2-hydroxy-4-methoxyphenyl)benzoxazole and benzothiazole to Fluorescent Probes Sensing pH and Metal Cations. *J. Org. Chem.* **2001**, *66*, 7328–7333. (d) Chen, M.; Lv, X.; Liu, Y.; Zhao, Y.; Liu, J.; Wang, P.; Guo, W. An 2-(2'-aminophenyl)benzoxazole-based OFF–ON fluorescent chemosensor for Zn<sup>2+</sup> in aqueous solution. *Org. Biol. Chem.* **2011**, *9*, 2345–2349.

(3) (a) Qian, Z.; Yang, M.; Li, R.; Li, D.; Zhang, J.; Xiao, Y.; Li, C.; Yang, R.; Zhao, N.; Xu, J. Fire-resistant, ultralight, superelastic and thermally insulated polybenzoxazole aerogels. *J. Mater. Chem. A* **2018**, *6*, 20769–20777. (b) Wu, C. C.; Tsay, P. Y.; Cheng, H. Y.; Bai, S. J. Polarized luminescence and absorption of highly oriented, fully conjugated, heterocyclic aromatic rigid-rod polymer poly-*p*-phenylenebenzobisoxazole. *J. Appl. Phys.* **2004**, *95*, 417–423. (c) Tamargo-Martínez, K.; Villar-Rodil, S.; Paredes, J. I.; Martínez-Alonso, A.; Tascón, J. M. D. Studies on the Thermal Degradation of Poly(*p*-phenylene benzobisoxazole). *Chem. Mater.* **2003**, *15*, 4052–4059. (d) Xue, P.; Chen, P.; Jia, J.; Xu, Q.; Sun, J.; Yao, B.; Lu, R. A triphenylamine-based benzoxazole derivative as a high-contrast piezofluorochromic material induced by protonation. *Chem. Commun.* **2014**, *50*, 2569–2571. (e) Wee, D.; Yoo, S.; Kang, Y. H.; Kim, Y. H.; Ka, J. W.; Cho, S. Y.; Lee, C.; Ryu, J.; Yi, M. H.; Jang, K. S. Poly(imide-benzoxazole) gate insulators with high thermal resistance for solution-processed flexible indium-zinc oxide thin-film transistors. *J. Mater. Chem. C* **2014**, *2*, 6395–6401. (f) Xu, Y.; Xiao, L.; Sun, S.; Pei, Z.; Pei, Y.; Pang, Y. Switchable and selective detection of Zn<sup>2+</sup> or Cd<sup>2+</sup> in living cells based on 3'-O-substituted arrangement of benzoxazole-derived fluorescent probes. *Chem. Commun.* **2014**, *50*, 7514–7516.

(4) (a) Riadi, Y.; Mamouni, R.; Azzalou, R.; El Haddad, M.; Routier, S.; Guillaumet, G.; Lazar, S. An efficient and reusable heterogeneous catalyst animal bone meal for facile synthesis of benzimidazoles, benzoxazoles, and benzothiazoles. *Tetrahedron Lett.* **2011**, *52*, 3492–3495. (b) Chen, F.; Shen, C.; Yang, D. A simple protocol for the synthesis of 2-arylbenzoxazoles by oxidation with *o*-iodoxybenzoic acid (IBX) and its application in the synthesis of arylbenzoxazole-containing amino acids. *Tetrahedron Lett.* **2011**, *52*, 2128–2131. (c) Chang, J.; Zhao, K.; Pan, S. Synthesis of 2-arylbenzoxazoles via DDQ promoted oxidative cyclization of phenolic Schiff bases—a solution-phase strategy for library synthesis. *Tetrahedron Lett.* **2002**, *43*, 951–954. (d) Dudd, L. M.; Venardou, E.; Garcia-Verdugo, E.; Licence, P.; Blake, A. J.; Wilson, C.; Poliakov, M. Synthesis of benzimidazoles in high-temperature water. *Green Chem.* **2003**, *5*, 187–192. (e) Chen, Y. X.; Qian, L. F.; Zhang, W.; Han, B. Efficient Aerobic Oxidative Synthesis of 2-Substituted Benzoxazoles, Benzothiazoles, and Benzimidazoles Catalyzed by 4-Methoxy-TEMPO. *Angew. Chem., Int. Ed.* **2008**, *47*, 9330–9333. (f) Sharma, H.; Singh, N.; Jang, D. O. A

ball-milling strategy for the synthesis of benzothiazole, benzimidazole and benzoxazole derivatives under solvent-free conditions. *Green Chem.* **2014**, *16*, 4922–4930.

(5) (a) Kaldhi, D.; Vodnala, N.; Gujjarappa, R.; Malakar, C. C.; Nayak, S.; Ravichandiran, V.; Hazra, C. K.; Malakar, C. C. Organocatalytic oxidative synthesis of C2-functionalized benzoxazoles, naphthoxazoles, benzothiazoles and benzimidazoles. *Tetrahedron Lett.* **2019**, *60*, 223–229. (b) Khalafi-Nezhad, A.; Panahi, F. Ruthenium-Catalyzed Synthesis of Benzoxazoles Using Acceptorless Dehydrogenative Coupling Reaction of Primary Alcohols with 2-Aminophenol under Heterogeneous Conditions. *ACS Catal.* **2014**, *4*, 1686–1692. (c) Endo, Y.; Bäckvall, J. E. Biomimetic Oxidative Coupling of Benzylamines and 2-Aminophenols: Synthesis of Benzoxazoles. *Chem. - Eur. J.* **2012**, *18*, 13609–13613. (d) Yu, J.; Xu, J.; Lu, M. Copper-catalyzed highly efficient aerobic oxidative synthesis of benzimidazoles, benzoxazoles and benzothiazoles from aromatic alcohols under solvent-free conditions in open air at room temperature. *Appl. Organomet. Chem.* **2013**, *27*, 606–610.

(6) (a) Urzúa, J. I.; Contreras, R.; Salas, C. O.; Tapia, R. A. N-Heterocyclic carbene copper (I) complex-catalyzed synthesis of 2-aryl benzoxazoles and benzothiazoles. *RSC Adv.* **2016**, *6*, 82401–82408. (b) Tiwari, A. R.; Bhanage, B. M. Copper-catalyzed synthesis of benzoxazoles via tandem cyclization of 2-halophenols with amidines. *Org. Biomol. Chem.* **2016**, *14*, 7920–7926. (c) Saha, P.; Ramana, T.; Purkait, N.; Ali, M. A.; Paul, R.; Punniyamurthy, T. Ligand-free Copper-Catalyzed Synthesis of Substituted Benzimidazoles, 2-Amino-benzimidazoles, 2-Aminobenzothiazoles, and Benzoxazoles. *J. Org. Chem.* **2009**, *74*, 8719–8725. (d) Peng, J.; Ye, M.; Zong, C.; Hu, F.; Feng, L.; Wang, X.; Wang, Y.; Chen, C. Copper-Catalyzed Intramolecular C–N Bond Formation: A Straightforward Synthesis of Benzimidazole Derivatives in Water. *J. Org. Chem.* **2011**, *76*, 716–719.

(7) (a) Nguyen, T. B.; Ermolenko, L.; Al-Mourabit, A. Iron Sulfide Catalyzed Redox/Condensation Cascade Reaction between 2-Amino/Hydroxy Nitrobenzenes and Activated Methyl Groups: A Straightforward atom Economical Approach to 2-Hetaryl-benzimidazoles and -benzoxazoles. *J. Am. Chem. Soc.* **2013**, *135*, 118–121. (b) Nguyen, T. B.; Ermolenko, L.; Al-Mourabit, A. Nitro-Methyl Redox Coupling: Efficient Approach to 2-Hetarylbenzothiazoles from 2-Halonitroarene, Methylhetarene, and Elemental Sulfur. *Org. Lett.* **2013**, *15*, 4218–4221. (c) Nguyen, T. B.; Le Bescont, J.; Ermolenko, L.; Al-Mourabit, A. Cobalt- and Iron-Catalyzed Redox Condensation of *o*-Substituted Nitrobenzenes with Alkylamines: A step-and Redox-Economical Synthesis of Diazaheterocycles. *Org. Lett.* **2013**, *15*, 6218–6221. (d) Nguyen, T. B.; Ermolenko, L.; Corbin, M.; Al-Mourabit, A. Fe/S-catalyzed decarboxylative redox condensation of arylacetic acids with nitroarenes. *Org. Chem. Front.* **2014**, *1*, 1157–1160.

(8) (a) Gan, H. Iron/S<sub>8</sub>-Catalyzed Redox Condensation of *o*-Nitroarenes with Arylmethyl Chloride: Synthesis of Benzimidazoles and Benzothiazoles. *Asian J. Org. Chem.* **2016**, *5*, 1111–1114. (b) Gan, H. Fe/S-Catalyzed Redox Condensation of *o*-Nitrophenols/thiophenols/anilines with Dibenzyl Disulfide: Access to 2-Arylbenzoxazoles. *ChemistrySelect* **2020**, *5*, 717–721.

(9) Lin, W. H.; Wu, W. C.; Selvaraju, M.; Sun, C. M. One-pot synthesis of benzazoles and quinazolinones via iron pentacarbonyl mediated carbonylation of aryl iodides under microwave irradiation. *Org. Chem. Front.* **2017**, *4*, 392–397.

(10) (a) Li, G.; Wang, J.; Yuan, B.; Zhang, D.; Lin, Z.; Li, P.; Huang, H. Iron-catalyzed one-pot synthesis of benzimidazoles from 2-nitroanilines and benzylic alcohols. *Tetrahedron Lett.* **2013**, *54*, 6934–6936. (b) Wu, M.; Hu, X.; Liu, J.; Liao, Y.; Deng, G. J. Iron-Catalyzed 2-Arylbenzoxazole Formation from *o*-Nitrophenols and Benzylic alcohols. *Org. Lett.* **2012**, *14*, 2722–2725. (c) Li, X.; Hu, R.; Tong, Y.; Pan, Q.; Miao, D.; Han, S. An efficient route for the synthesis of benzimidazoles via a hydrogen-transfer strategy between *o*-nitroanilines and alcohols. *Tetrahedron Lett.* **2016**, *57*, 4645–4649. (d) Das, S.; Mallick, S.; De Sarkar, S. Cobalt-Catalyzed Sustainable Synthesis of Benzimidazoles by Redox-Economical Coupling of *o*-Nitroanilines and Alcohols. *J. Org. Chem.* **2019**, *84*, 12111–12119. (e) Nguyen, T. B.; Ermolenko, L.; Al-Mourabit, A. Sodium Sulfide: A

Sustainable Solution for Unbalanced Redox Condensation Reaction between *o*-nitroanilines and alcohols catalyzed by an Iron-Sulfur System. *Synthesis* **2015**, *47*, 1741–1748. (f) Chaurasia, S. R.; Bhanage, B. M. CuNiFe a Magnetic Nano-Catalyst: an Efficient Catalyst for the Selective Synthesis of Benzoxazoles. *ChemistrySelect* **2018**, *3*, 7963–7969. (g) Guan, Q.; Sun, Q.; Wen, L.; Zha, Z.; Yang, Y.; Wang, Z. The synthesis of benzimidazoles via a recycled palladium catalysed hydrogen transfer under mild conditions. *Org. Biomol. Chem.* **2018**, *16*, 2088–2096.

(11) (a) Quintard, A.; Rodriguez, J. Iron Cyclopentadienone Complexes: Discovery, Properties, and Catalytic Reactivity. *Angew. Chem., Int. Ed.* **2014**, *53*, 4044–4055. (b) Yan, T.; Feringa, B. L.; Barta, K. Iron catalysed direct alkylation of amines with alcohols. *Nat. Commun.* **2014**, *5*, No. 5602. (c) Quintard, A.; Constantieux, T.; Rodriguez, J. An Iron/Amine-Catalyzed Cascade Process for the Enantioselective Functionalization of Allylic Alcohols. *Angew. Chem., Int. Ed.* **2013**, *52*, 12883–12887. (d) Elangovan, S.; Sortais, J. B.; Beller, M.; Darcel, C. Iron-Catalyzed  $\alpha$ -Alkylation of Ketones with Alcohols. *Angew. Chem., Int. Ed.* **2015**, *54*, 14483–14486. (e) Polidano, K.; Allen, B. D.; Williams, J. M.; Morrill, L. C. Iron-Catalyzed Methylation Using the Borrowing Hydrogen Approach. *ACS Catal.* **2018**, *8*, 6440–6445. (f) Bettoni, L.; Gaillard, S.; Renaud, J. L. Iron-Catalyzed  $\alpha$ -Alkylation of Ketones with Secondary Alcohols: Access to  $\beta$ -Disubstituted Carbonyl Compounds. *Org. Lett.* **2020**, *22*, 2064–2069. (g) Bettoni, L.; Gaillard, S.; Renaud, J. L. Iron-Catalyzed  $\beta$ -Alkylation of Alcohols. *Org. Lett.* **2019**, *21*, 8404–8408. (h) Tang, Y.; Meador, R. I.; Malinchak, C. T.; Harrison, E. E.; McCaskey, K. A.; Hempel, M. C.; Funk, T. W. Cyclopentadienone iron-Catalyzed Transfer Dehydrogenation of Symmetrical and Unsymmetrical Diols to Lactones. *J. Org. Chem.* **2020**, *85*, 1823–1834.

(12) Putta, R. R.; Chun, S.; Lee, S. B.; Oh, D.-C.; Hong, S. Iron-Catalyzed Acceptorless Dehydrogenative Coupling of Alcohols With Aromatic Diamines: Selective Synthesis of 1, 2-Disubstituted Benzimidazoles. *Front. Chem.* **2020**, *8*, 429.

(13) Moulin, S.; Dentel, H.; Pagnoux-Ozherelyeva, A.; Gaillard, S.; Poater, A.; Cavallo, L.; Lohier, J.-F.; Renaud, J.-L. Bifunctional (Cyclopentadienone) Iron–Tricarbonyl Complexes: Synthesis, Computational Studies and Application in Reductive Amination. *Chem. - Eur. J.* **2013**, *19*, 17881–17890.

(14) Dambatta, M. B.; Polidano, K.; Northey, A. D.; Williams, J. M.; Morrill, L. C. Iron-Catalyzed Borrowing Hydrogen C-Alkylation of Oxindoles with Alcohols. *ChemSusChem* **2019**, *12*, 2345–2349.

(15) Lu, X.; Long, T. E. *o*-Nitrophenyl Sulfoxides: Efficient Precursors for the Mild Preparation of Alkenes. *J. Org. Chem.* **2010**, *75*, 249–252.

(16) Hong, J. E.; Jung, Y.; Park, Y.; Park, Y. Highly Selective Synthesis of Hydrazoarenes from Nitroarenes via Polystyrene-Supported Au-Nanoparticle-Catalyzed Reduction: Application to Azoarenes, aminoarenes, and 4,4'-Diaminobiaryls. *ACS Omega* **2020**, *5*, 7576–7583.

(17) Shen, H. J.; Duan, Y. N.; Zheng, K.; Zhang, C. Redetermination of the Structure of a Water-Soluble Hypervalent Iodine (V) Reagent AIBX and its Synthetic Utility in the Oxidation of Alcohols and Synthesis of Isoxazoline *N*-Oxides. *J. Org. Chem.* **2019**, *84*, 14381–14393.